Crossmark

A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee

Crossref DOI link: https://doi.org/10.1186/s40001-018-0349-2

Published Online: 2018-10-24

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Delgado-Enciso, Ivan https://orcid.org/0000-0001-9848-862X
Paz-Garcia, Juan

Valtierra-Alvarez, Jose

Preciado-Ramirez, Jorge

Almeida-Trinidad, Roman

Guzman-Esquivel, Jose

Mendoza-Hernandez, Martha A.

Garcia-Vega, Alberto

Soriano-Hernandez, Alejandro D.

Cortes-Bazan, Jose L.

Galvan-Salazar, Hector R.

Cabrera-Licona, Ariana

Rodriguez-Sanchez, Iram P.

Martinez-Fierro, Margarita L.

Delgado-Enciso, Josuel

Paz-Michel, Brenda
Clinical Trials ^BETA

Clinical trials referenced in this document:

rpcec00000250 at Cuban Public Registry of Clinical Trials

Documents that mention this clinical trial

A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee
https://doi.org/10.1186/s40001-018-0349-2
Funding

Funding for this research was provided by:

INFRAESTRUCTURA CONACYT 2016 (270485)

FOSISS CONACYT 2016 (272792)
License Information

Text and Data Mining valid from 2018-10-24

Version of Record valid from 2018-10-24
More Information

Article History

Received: 16 March 2018

Accepted: 15 October 2018

First Online: 24 October 2018

Document is current

Any future updates will be listed below